Laali Azadeh, Tabibzadeh Alireza, Esghaei Maryam, Yousefi Parastoo, Soltani Saber, Ajdarkosh Hossein, Mosavi-Jarrahi Alireza, Karbalaie Niya Mohamad Hadi
Department of Infectious Diseases, Firouzgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Adv Biomed Res. 2020 Dec 23;9:74. doi: 10.4103/abr.abr_73_20. eCollection 2020.
Since the start of coronavirus epidemic in Wuhan, China, in early December 2019, many literatures addressed its epidemiology, virology, and clinical presentation. In this review, we systematically reviewed the published literature in the field of liver function tests profile in COVID-19 patients at the admission time.
systematic literature search were performed in EMBASE, PubMed, Science Direct, and Scopus using "severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2)", "SARS," "SARS-CoV," "coronavirus," "novel coronavirus," "liver," "hepatitis," "Liver function" keywords. The search was limited to range from 2019 to May 19, 2020.
From a total 7298 articles, 145 were screened and 18 were eligible for further analysis. The highest rate of liver associated comorbidities was reported 11%. The aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were the most frequent assessed enzymes. Increase in AST level was seen in 10%-53% of patients while The ALT increase was seen in 5%-28% of COVID-19 patients at the admission time. The prothrombin time was increase in 7%-12% of patients and the D-dimer was reports increase in 14%-36% of COVID-19 patients at the admission time. Furthermore, albumin decrease was seen in 6%-98% of COVID-19 patients at the admission time.
In conclusion, by using the results of study, it could be suggested that the liver function tests assessment is critical assessment in COVID-19 patients at the admission time. This liver function test could be used as potential prognostic factor in COVID-19 severity in future.
自2019年12月初中国武汉爆发冠状病毒疫情以来，许多文献探讨了其流行病学、病毒学及临床表现。在本综述中，我们系统回顾了已发表的关于COVID-19患者入院时肝功能检查情况的文献。
在EMBASE、PubMed、Science Direct和Scopus数据库中进行系统文献检索，使用“严重急性呼吸综合征冠状病毒2（SARS-CoV-2）”“SARS”“SARS-CoV”“冠状病毒”“新型冠状病毒”“肝脏”“肝炎”“肝功能”等关键词。检索范围限定为2019年至2020年5月19日。
从总共7298篇文章中筛选出145篇，18篇符合进一步分析的条件。报告的肝脏相关合并症最高发生率为11%。天冬氨酸转氨酶（AST）和丙氨酸转氨酶（ALT）是最常检测的酶。入院时，10% - 53%的患者AST水平升高，5% - 28%的COVID-19患者ALT升高。7% - 12%的患者凝血酶原时间延长，14% - 36%的COVID-19患者入院时D - 二聚体升高。此外，入院时6% - 98%的COVID-19患者白蛋白降低。
总之，根据研究结果表明，肝功能检查评估在COVID-19患者入院时是一项关键评估。这种肝功能检查未来可能作为COVID-19严重程度的潜在预后因素。
